Mineralys Therapeutics MLYS
NASDAQ MLYS
$21.10 -0.48 (-2.22%)
At close: Oct 21, 2026 · 4:00 PM EDT

Mineralys Therapeutics (MLYS) Capital Expenditures (2024 - 2025)

Updated

Mineralys Therapeutics' Capital Expenditures came in at $15,000 for Q4 2025.

Analysis

Mineralys Therapeutics (MLYS) Capital Expenditures (2024 - 2025) Analysis & Trends

  • Going back by year, Capital Expenditures was $96,000 in FY2024.
  • The Q4 2025 figure represents the highest quarterly Capital Expenditures since Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 2.93 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 1.32 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 322.00 Mn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 893.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 321.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 1.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 513.00 Mn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 140.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 533.00 Mn
10 Mineralys Therapeutics 1.79 Bn -765.35 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 15,000.00
Sep 30, 2024 37,000.00
Mar 31, 2024 59,000.00
API Access

Mineralys Therapeutics Capital Expenditures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-expenditures&ticker=MLYS&period=max&api_key=YOUR_API_KEY